R&D Systems™ Recombinant Human CD96 Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Manufacturer: R&D Systems™ 9360CD050
DescriptionMeasured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD ) is immobilized at 1 μg/mL, 100 μL/well, the concentration of Recombinant Human CD96 Fc Chimera that produces 50% of the optimal binding response is 0.3-1.8 μg/mL.
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.|
|Human embryonic kidney cell, HEK293-derived human CD96 protein Human CD96 (Lys25-Met519) (N-terminus) Accession # P40200-1 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
|<0.10 EU / 1 µg of the protein by the LAL method.|
|Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.|
|M.W. (Observed): 131 - 160 kDa, reducing conditions; M.W. (theoretical): 81 kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|CD96, CD96 antigenMGC22596, CD96 molecule, DKFZp667E2122, T cell-activated increased late expression protein, TACTILE, TACTILEincreased late expression, T-cell surface protein tactile|
|Reconstitute at 500 µg/mL in PBS.|